Floatz logo

Blinatumomab

Stem Cell Leukemia

SWOG Cancer Research Networkmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

79 Active assets in the Stem Cell Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Children's Oncology Group
Phase 3BB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
University of Washington
Phase 3BB
Daunorubicin
SWOG Cancer Research Network
Phase 3BB
MERCAPTOPURINE ANHYDROUS
SWOG Cancer Research Network
Phase 3BB
PEGASPARGASE
Children's Oncology Group
Phase 3BB

View all 50 →

Same molecule, other indications

Blinatumomab is also rated in:

precursor B-cell acute lymphoblastic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BBB
Indicative ·
72 / 100
View asset →
Precursor B-Cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →